New hope, old challenges in myelodysplastic syndromes The Lancet Haematology +++ +...

Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00256-X/abstract?utm_campaign=update-lanhae&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanhae&_hsenc=p2ANqtz--lJphX2Z9gukRpinCdYh8XwWpt9ehcFQU62YOWIsyh6C9x0Cb5A6UX_SEhePmxWpv3eLvQdTBn20YaIK_4OPY0y6VOWw&_hsmi=390180994&utm_content=389971974&utm_source=hs_email Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00264-9/abstract?utm_campaign=update-lanhae&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanhae&_hsenc=p2ANqtz--m93_jpOief7_eOUwuMH9S9AgEGQe1WFeV56A7ERhM0xmnvGklslnvQ97085e-jDx-VxLk0J2KUsTSMhu7AYwErJAKDA&_hsmi=390180994&utm_content=389971974&utm_source=hs_email New hope, old challenges in myelodysplastic syndromes The Lancet Haematology https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00292-3/fulltext?dgcid=hubspot_update_feature_updatealerts_lanhae&utm_campaign=update-lanhae&utm_medium=email&_hsenc=p2ANqtz-_u36LjCHY1b4nqtbX8rbTkr5qb4Su6CTAwC7qpbEhI-HA4dBvt_VqFBGFSsa5tgTq_scNhrdeOOje3ECkPC3bYw8Nd4g&_hsmi=390180994&utm_content=389971974&utm_source=hs_email Nov 2025 Volume 12Number 11e851-e926 https://www.thelancet.com/journals/lanhae/issue/vol12no11/PIIS2352-3026(25)X0011-9